A five‐gene hepatic signature including NETO2 may play a feasible role in the prediction of tumour growth and risk of death in patients with hepatocellular carcinoma (HCC), suggesting a useful molecular tool for therapeutic management of HCC patients.6 The gene discussed is NETO2; the disease is neoplasm.